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Context
Intubation and mechanical ventilation for respiratory failure in the immunosuppressed patient has a mortality rate ranging from 60 to 100%. Aggressive measures to avoid intubation may, therefore, improve outcome in these patients and avoid invasive therapy, which is often futile. Noninvasive ventilation (NIV) at an early stage in the respiratory failure of these patients may achieve this goal. This trial compares the efficacy of NIV with standard medical therapy.
Significant findings
Requirement for intubation, complications, and ICU and hospital mortality were significantly better in those patients receiving early NIV. Hospital mortality was 50% and 81% (P = 0.02) for the NIV and conventional groups, respectively. Patients who required intubation and mechanical ventilation in either group, had a 100% mortality. In the immunocompromised, initiation of NIV early in the course of hypoxic respiratory failure prevents intubation, reduces complications, and thereby improves survival.
Comments
Despite the small numbers involved in this trial, the findings are powerful and important. The futility of invasive ventilation in this patient population has long been recognised 3/4 as they succumb to nosocomial pneumonia. However, support during the hypoxic period, which avoids the lethal complications of nosocomial infection to which they are so prone may buy time to allow life-saving therapies, such as antibiotics, to work. NIV appears to buy this time, although it may be that a simpler form of ventilatory support (continuous positive airway pressure [CPAP] ) is as effective and should be the subject of future research. However, to date trials in immunocompetent patients have so far shown that CPAP is no better than conventional oxygen therapy in supporting respiratory failure. Although
